BIIB · Biogen Inc. · Investor Relations

EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT study Publication follows a recent FDA label update to expand EMPAVELI’s indication to

Cambridge, Mass.— Biogen Inc. (Nasdaq: BIIB) today announced it will report third quarter 2026 financial results Wednesday, October 28, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI ® Pen”, the subcutaneous

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines – – New data showed substantial

The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– – Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile – –New

An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 24th Annual Global Healthcare Conference. The webcast will be live on Monday, Sept 14, 2026, at 9:15

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Robin Kramer, Chief Financial Officer, and Adam Keeney, Head of Corporate Development, will participate in a fireside chat during the Wells Fargo 21st Annual Healthcare Conference. The webcast will be live on Wednesday, Sept 9,

LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that once weekly

Lead program now in Phase 1 development CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A.

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc.

Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc.

Cambridge, Mass.— Biogen Inc. (Nasdaq: BIIB) today announced it will hold an investor webcast on Tuesday, July 14, 2026, from the Alzheimer's Association International Conference (AAIC) in London. The Company will host a live webcast with Biogen management at 12:00 p.m. ET.

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026 Lecanemab presentations will highlight emerging data on subcutaneous

Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and

Cambridge, Mass.— Biogen Inc. (Nasdaq: BIIB) today announced it will report second quarter 2026 financial results Wednesday, July 29, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slowing of neurodegeneration and clinically meaningful improvements in motor function following

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting

Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc.

Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of care Findings showed results in favor of dapirolizumab